<DOC>
	<DOCNO>NCT02947347</DOCNO>
	<brief_summary>The purpose study evaluate whether addition ibrutinib result prolongation progression-free survival ( PFS ) compare rituximab alone treatment naïve subject follicular lymphoma .</brief_summary>
	<brief_title>Study Ibrutinib Rituximab Treatment Naïve Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically confirm diagnosis follicular lymphoma CD20+ ( Grade 1 , 2 3a ) Ann Arbor Stage II , III IV disease . Measurable disease Subjects 70 year age older ; OR subject 6069 year age one comorbidities . Meets one Groupe d'Etude de Lymphomes Folliculaire ( GELF ) criterion . Adequate hematologic function within protocoldefined parameter . Adequate hepatic renal function within protocoldefined parameter . ECOG performance status score 02 . Transformed lymphoma Prior treatment follicular lymphoma Central nervous system lymphoma leptomeningeal disease Currently active , clinically significant cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>